This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Acorda Therapeutics Inc (ACOR)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) 16.44M 154.96M 30.60M -11.77M
Operating Gains/Losses -182.00K -701.00K 639.00K -246.50K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -4.46M -3.50M -556.00K -16.53M
(Increase) Decrease in Inventories -5.12M 7.43M 10.04M -31.53M
(Increase) Decrease In Other Current Assets 0.00 0.00 -372.00K -878.00
(Decrease) Increase In Payables -5.78M 11.74M -6.11M 24.71M
(Decrease) Increase In Other Current Liabilities 18.00K -725.00K -1.14M 0.00
(Increase) Decrease In Other Working Capital -5.39M -12.28M -7.22M -8.25M
Other Non-Cash Items 25.05M 22.08M 32.34M 17.78M
Net Cash From Continuing Operations 39.28M 52.12M 66.34M -19.22M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 39.28M 52.12M 66.34M -19.22M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 191.00M 264.75M 227.50M 325.75M
Purchases of Property, Plant & Equipment -7.16M -13.58M -5.79M -9.44M
Acquisitions -7.50M 0.00 0.00 0.00
Purchases of Short-Term Investments -221.43M -322.46M -266.74M -310.95M
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -45.09M -71.28M -45.02M 5.35M
Issuance of Debt 0.00 0.00 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 12.79M 4.34M 3.96M 8.37M
Repayment of Long-Term Debt -909.00K -1.25M -1.96M 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 -328.76K
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 91.00K 0.00 0.00 -6.85M
Net Cash From Financing Activities 11.97M 3.09M 2.00M 1.19M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 6.16M -16.08M 23.31M -12.67M
ACOR News

ACOR Acorda Therapeutics Inc

Analysts Ratings for ACOR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 4 4 3
Moderate Buy 0 0 0 0
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ACOR ANALYST REPORT

Brokerage Partners

ACOR Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs